Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment options, including convalescent plasma transfusion. The hypothesis is that convalescent plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in ICU
Epistemonikos ID: c77ab6b3604b885515ff176d938c51af7a1742d7
First added on: May 19, 2020